HDAC inhibition potentiates immunotherapy in triple negative breast cancer

Manuela Terranova-Barberio(University of California, San Francisco), Pamela N. Münster(University of California, San Francisco), Nela Pawłowska(University of California, San Francisco), Alfredo Budillon(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Scott Thomas(Memorial Hospital of South Bend), Jeenah Park(University of California, San Francisco), Michael Rosenblum(Johns Hopkins University), Gregor Krings(Cleveland Clinic), Niwa Ali(University of California, San Francisco)
Oncotarget
December 12, 2017
10.18632/oncotarget.23169
Cited by 180

Related Papers

Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial
|The Lancet|2019|891
Comprehensive analysis of normal adjacent to tumor transcriptomes
|Nature Communications|2017|663
Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer
|Nature Medicine|2016|539
Mutations in Sarcomere Protein Genes in Left Ventricular Noncompaction
|Circulation|2008|454
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
|Nature Communications|2020|342